Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06772415 | A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 163 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06782334 | AMT-116 in Patients with Solid Tumors | recruiting | Phase 1 / Phase 2 | 144 | Multitude Therapeutics Inc.INDUSTRY | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06600022 | Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours. | recruiting | Phase 1 / Phase 2 | 441 | Sinocelltech Ltd.INDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06770764 | Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 50 | Trutino Biosciences Inc.INDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06643754 | A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors | recruiting | Phase 1 / Phase 2 | 115 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06763159 | A Study of HS-20124 in Patients with Advanced Solid Tumors | recruiting | Phase 1 | 450 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06764836 | A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 108 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06090266 | A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | recruiting | Phase 1 / Phase 2 | 168 | OncoResponse, Inc.INDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06686745 | Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 130 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06760117 | UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors | recruiting | Phase 1 | 39 | Sun Yat-sen UniversityOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT05417321 | A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 80 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 2 | Jan 3, 2025 | clinicaltrials |
| NCT06404905 | Clinical Trial of BT02 in Patients With Advanced Solid Tumors(BT02) | recruiting | Phase 1 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03866525 | OH2 Oncolytic Viral Therapy in Solid Tumors | recruiting | Phase 1 / Phase 2 | 300 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT05877430 | Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | recruiting | Phase 1 / Phase 2 | 160 | CJ Bioscience, Inc.INDUSTRY | 2 | Dec 20, 2024 | clinicaltrials |
| NCT06332430 | Intratumoral CAN2109 in Subjects With Solid Tumors | recruiting | Phase 1 | 27 | Canwell Biotech LimitedINDUSTRY | 1 | Dec 19, 2024 | clinicaltrials |
| NCT05315167 | A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 267 | Zhuhai Yufan Biotechnologies Co., LtdINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06728189 | A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid Tumors | recruiting | Phase 1 | 13 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06726564 | A Study of MT027 in Patients with Pleural Malignant Tumors | recruiting | Phase 1 | 18 | Suzhou Maximum Bio-tech Co., Ltd.INDUSTRY | 1 | Dec 10, 2024 | clinicaltrials |
| NCT06426680 | A Study of the ILB-3101 in Patients with Advanced Solid Tumors | recruiting | Phase 1 | 240 | Innolake BiopharmINDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06302062 | Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors(TAL-T) | recruiting | Phase 1 | 23 | Guangzhou FineImmune Biotechnology Co., LTD.INDUSTRY | 1 | Dec 3, 2024 | clinicaltrials |
| NCT05667194 | Phase 1 Trial of KH617 | recruiting | Phase 1 | 45 | Sichuan Honghe Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 27, 2024 | clinicaltrials |
| NCT05824975 | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | recruiting | Phase 1 / Phase 2 | 358 | GI Innovation, Inc.INDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT06117566 | A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Shanghai Jiatan Pharmatech Co., LtdINDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06084286 | Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors | recruiting | Phase 1 | 29 | Sichuan UniversityOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06158477 | A Clinical Trial Evaluating JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 75 | Chengdu JOYO pharma Co., Ltd.INDUSTRY | 1 | Nov 18, 2024 | clinicaltrials |
| NCT04787042 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | recruiting | Phase 1 / Phase 2 | 316 | Simcha IL-18, Inc.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT05156203 | Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors | recruiting | Phase 1 | 30 | Taivex Therapeutics CorporationINDUSTRY | 1 | Nov 12, 2024 | clinicaltrials |
| NCT05983523 | A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 54 | PharmaEngineINDUSTRY | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06190886 | A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 26 | Proviva Therapeutics, Inc.INDUSTRY | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06622486 | First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 50 | Egle TherapeuticsINDUSTRY | 2 | Nov 7, 2024 | clinicaltrials |
| NCT05772455 | A Study of XZB-0004 in Patients With Solid Tumors | recruiting | Phase 1 | 128 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 28, 2024 | clinicaltrials |
| NCT04093466 | A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors | recruiting | Phase 1 | 126 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04387916 | A Study of KC1036 in Patients with Advanced Solid Tumors | recruiting | Phase 1 | 207 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06632574 | A Clinical Study of Paclitaxel Cationic Liposomes for the Treatment of Patients With Advanced Solid Tumors | recruiting | Phase 1 | 60 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06615193 | A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor | recruiting | Phase 1 | 111 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06259552 | A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors(SPX-303) | recruiting | Phase 1 | 232 | SparX Biotech(Jiangsu) Co., Ltd.OTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT03891706 | Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 30 | Guangzhou FineImmune Biotechnology Co., LTD.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05367778 | Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 176 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05773937 | A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors | recruiting | Phase 1 | 40 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06525298 | EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors | recruiting | Phase 1 / Phase 2 | 144 | Eisbach Bio GmbHINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06589401 | Oral Paclitaxel for Patients with Advanced Solid Tumors | recruiting | Phase 1 | 70 | InnoUp Farma S.L.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06592417 | To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors | recruiting | Phase 1 | 140 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06548672 | A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer | recruiting | Phase 1 | 148 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06452160 | A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 103 | BridGene Biosciences Inc.INDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06536400 | Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation | recruiting | Phase 1 | 316 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06257680 | A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 15 | Beijing Xunsheng Biomedical Research Co., Ltd.INDUSTRY | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06514651 | MAQ-001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 30 | MabQuest SAINDUSTRY | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06332170 | ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 610 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT06336707 | HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 1,048 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT05979155 | A Study of NWY001 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 196 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jul 16, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jan 22, 2025source: clinicaltrials